Source comparison
PT-141 Myths Debunked: Route Comparison
One critical aspect of PT-141 myths debunked involves administration routes. The table below compares subcutaneous injection (the FDA-approved route) with intranasal and oral administration. Two routes frequently promoted in grey-market peptide sources. Subcut
This comparison does not assign a generated winner or score.
- One critical aspect of PT-141 myths debunked involves administration routes. The table below compares subcutaneous injection (the FDA-approved route) with intranasal and oral administration. Two routes frequently promoted in grey-market peptide sources.
- Subcutaneous Injection (1.75 mg)
- ~100% (reference standard)
- 30–60 minutes
- Phase III RCTs, FDA-approved
- Only route with demonstrated efficacy in double-blind trials
- Intranasal Spray
- ~3–8% (estimated)
- Variable, often >90 min
- Early-phase pilot studies only
- No large-scale trials; highly inconsistent plasma levels
- Oral Tablet/Capsule
- <1% (degraded by gastric enzymes)
- Not applicable
- None. No oral formulation studied
- Peptide bond hydrolysis destroys the molecule before absorption
- Sublingual
- Unknown, likely <5%
- Variable
- Anecdotal reports only
- No pharmacokinetic data; mucous membrane absorption unverified
- The subcutaneous route delivers predictable, reproducible plasma concentrations because it bypasses first-pass hepatic metabolism and avoids enzymatic degradation in the GI tract. Intranasal formulations were explored in early trials but abandoned due to inconsistent absorption. Mucosal permeability varies by individual, nasal congestion blocks absorption entirely, and peptide aggregation in spray formulations reduces bioavailability. Oral administration is pharmacologically implausible. PT-141 is a cyclic heptapeptide with multiple peptide bonds that are hydrolyzed by gastric acid and pancreatic proteases within minutes of ingestion. No oral formulation has ever been studied in clinical trials, and no mechanism exists for meaningful absorption.
- PT-141 myths debunked by pharmacokinetics: if a vendor claims oral or intranasal PT-141 is "just as effective" as subcutaneous, they are either misinformed or deliberately misrepresenting the evidence. Real Peptides supplies research-grade bremelanotide in lyophilized powder form for reconstitution with bacteriostatic water, designed specifically for subcutaneous administration in controlled laboratory settings.